$608.02
0.35% yesterday
Nasdaq, Nov 25, 09:16 pm CET
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

argenx SE ADR Stock price

$605.66
+48.83 8.77% 1M
+238.59 65.00% 6M
+225.23 59.20% YTD
+109.89 22.17% 1Y
+328.75 118.72% 3Y
+459.10 313.25% 5Y
+582.66 2,533.30% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.26 0.04%
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization $36.56b
Enterprise Value $33.49b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.74
P/S ratio (TTM) P/S ratio 22.64
P/B ratio (TTM) P/B ratio 8.50
Revenue growth (TTM) Revenue growth 101.07%
Revenue (TTM) Revenue $1.61b
EBIT (operating result TTM) EBIT $-396.71m
Free Cash Flow (TTM) Free Cash Flow $-146.69m
EPS (TTM) EPS $-3.50
P/E forward 296.16
P/S forward 17.08
EV/Sales forward 15.65
Short interest 2.84%
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a argenx SE ADR forecast:

29x Buy
88%
4x Hold
12%

Analyst Opinions

33 Analysts have issued a argenx SE ADR forecast:

Buy
88%
Hold
12%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1,615 1,615
101% 101%
100%
- Direct Costs 279 279
62% 62%
17%
1,336 1,336
112% 112%
83%
- Selling and Administrative Expenses 777 777
74% 74%
48%
- Research and Development Expense 843 843
31% 31%
52%
-285 -285
38% 38%
-18%
- Depreciation and Amortization 112 112
6% 6%
7%
EBIT (Operating Income) EBIT -397 -397
30% 30%
-25%
Net Profit -205 -205
49% 49%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
about 7 hours ago
November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
Neutral
GlobeNewsWire
6 days ago
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a globa...
Neutral
Business Wire
7 days ago
BOSTON--(BUSINESS WIRE)--Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid-toxicity clinical outcome assessments (COAs) across argenx's development programs for differentiated immunology therapeutics. The STOX Suite comprises first-in-class digit...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,148
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today